Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$16.47 USD
+0.81 (5.17%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $16.45 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Phathom Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 168 | 172 | 135 | 126 | 106 |
Income After Depreciation & Amortization | -167 | -172 | -135 | -126 | -106 |
Non-Operating Income | 8 | 2 | -2 | 1 | -145 |
Interest Expense | 42 | 27 | 7 | 5 | 4 |
Pretax Income | -202 | -198 | -144 | -129 | -255 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -202 | -198 | -144 | -129 | -255 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -202 | -198 | -144 | -129 | -255 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -165 | -170 | -131 | -124 | -106 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 4 | 2 | 0 |
Income After Depreciation & Amortization | -167 | -172 | -135 | -126 | -106 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.29 | 39.12 | 37.00 | 33.23 | 11.37 |
Diluted EPS Before Non-Recurring Items | -2.53 | -5.05 | -3.89 | -3.88 | -13.98 |
Diluted Net EPS (GAAP) | -3.93 | -5.05 | -3.89 | -3.88 | -22.45 |
Fiscal Year end for Phathom Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 7.32 | 1.91 | 0.68 | 0.00 |
Cost Of Goods | NA | 1.38 | 0.43 | 0.17 | 0.00 |
Gross Profit | NA | 5.95 | 1.49 | 0.52 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 83.25 | 71.44 | 70.39 | 35.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -77.30 | -69.95 | -69.87 | -35.66 |
Non-Operating Income | NA | 3.62 | 4.27 | 3.33 | 2.52 |
Interest Expense | NA | 17.76 | 17.17 | 13.03 | 10.11 |
Pretax Income | NA | -91.45 | -82.85 | -79.57 | -43.24 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -91.45 | -82.85 | -79.57 | -43.24 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -91.45 | -82.85 | -79.57 | -43.24 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 58.56 | 58.37 | 57.29 | 56.78 |
Diluted EPS Before Non-Recurring Items | NA | -1.35 | -1.42 | -0.80 | -0.76 |
Diluted Net EPS (GAAP) | NA | -1.56 | -1.42 | -1.44 | -0.76 |